Regencell Bioscience Holdings Limited (RGC) Stock Price, Financials & Summary

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−387.3x

Market Cap

$3.41B

MomentumView details →

1D Return

+6.33%

YTD Return

−66.76%

RSI (14)

64.0

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−387.3x

Market Cap

$3.41B

RSI (14)

64.0

MomentumView details →

1D Return

+6.33%

YTD Return

−66.76%

SummaryUpdated Dec 1, 2025

Regencell Bioscience Holdings Limited (NASDAQ:RGC) is a Traditional Chinese Medicine (TCM) bioscience company founded in 2014 and headquartered in Causeway Bay, Hong Kong. The company went public on July 16, 2021, and focuses on developing innovative treatments for neurocognitive disorders using traditional Chinese medicine principles combined with modern scientific research methods. Regencell is currently in the research and development phase, with no commercial products yet generating revenue.

Ask drillr about Regencell Bioscience Holdings Limited →

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−730.15%

ROA (TTM)

−295.46%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

+100.00%

EPS YoY

−13.50%

FCF YoY

+54.13%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+17.24%

EBITDA YoY

+40.69%

EarningsView details →

EPS (Actual)

−$0.01

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.32x

Current Ratio

1.42x

Quick Ratio

1.42x

Div Yield

—

Div Rate

—

Div Growth 1Y

+0.00%

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−8.90M

Op. CF (TTM)

−4.59M

Next earningsOct 28, 2026 →

Latest newsMore news →

No recent news for RGC.

Similar companies

威尔药业603351.SH 康惠股份603139.SH 益佰制药600594.SH 司太立603520.SH 灵康药业603669.SH Shandong Xinhua Pharmaceutical Company Limited00719.HK Find similar companies →

Latest newsMore news →

No recent news for RGC.